{"id":511741,"date":"2021-07-12T08:18:10","date_gmt":"2021-07-12T12:18:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/"},"modified":"2021-07-12T08:18:10","modified_gmt":"2021-07-12T12:18:10","slug":"brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/","title":{"rendered":"Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, July  12, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n178-VTWIKL4zwdFbHt0AE-b6N5XnPXAGaXOtInV4yYlbWNHUTDX29g5I9tFwcs2DUegRjKS8ukVzQUdWNRJiS1ddxxHWqzh8FACVD8qyrhtUz7mKFSJAddTPqpC1BHL\" rel=\"nofollow noopener\" target=\"_blank\">Brooklyn ImmunoTherapeutics LLC<\/a> (NYSE American: BTX) (\u201cBrooklyn\u201d or \u201cthe Company\u201d), a biopharmaceutical company focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that Chief Executive Officer Howard J. Federoff, M.D., Ph.D., will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 \u2013 15, 2021.<\/p>\n<p align=\"justify\">Dr. Federoff will deliver his corporate presentation on July 15 at 9:00am ET.<\/p>\n<p align=\"justify\">To receive additional information, request an invitation or to schedule a one-on-one meeting, please email <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X9ciqs_-wCdCqo7JSyelesNpgvEb1ZvlNCu8sfuArKXOUgHvfaH5jzMT7G4WvjR8BrYgKvcn-ISVXk6BkPhUDzyG3nhRgEUxEgWvyaKbDQg76_7mB54NFOjwXDuGC1zE\" rel=\"nofollow noopener\" target=\"_blank\">angie.goertz@issuerdirect.com<\/a>.<\/p>\n<p align=\"justify\">Investors can register <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8RTWPLQR4Hut6eiz9rHm1po9uOI-N3hG6OMyGwrSJqBh9W0F1vO4B7jIk5gAGeMV3O7RwEO2VAiXdgDLJrqa9gnOGWKZjkHxmS3x2_w-CodOwkqlXfWCyzCeYsFjPUgE\" rel=\"nofollow noopener\" target=\"_blank\">here.<\/a><\/p>\n<p align=\"justify\">\n        <strong>About Brooklyn ImmunoTherapeutics<\/strong><br \/>\n        <br \/>Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing\/cell therapy technology through its option agreement with Factor Bioscience\/Novellus.<\/p>\n<p align=\"justify\">Brooklyn\u2019s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.<\/p>\n<p align=\"justify\">For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>CORE IR<br \/>516-222-2560<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FUc3vMhl7gvk5OJ7bs-WFlLkNY0rt-Ti0FaLOQsq9xaJgHgIaSKGpYdwD4GWYBp0BYth7AVwilkUo03r-ZzAZlEWPaIgZGXHUE-mE8mpndw=\" rel=\"nofollow noopener\" target=\"_blank\">investors@brooklynitx.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Jules Abraham<br \/>CORE IR<br \/>917-885-7378<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y0daU1Zqd-TkigwcfLJYlBpgxJ-nXLs6EuAxJtExid50AVlVZRbDJZsqewhmciNKz0f84LHsxqUnjaK3VTJMug==\" rel=\"nofollow noopener\" target=\"_blank\">julesa@coreir.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQ2NSM0MjkxNzYzIzIyMTAyODA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/bce52192-462a-4540-8abd-a9b86e1c6700\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) &#8212; Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (\u201cBrooklyn\u201d or \u201cthe Company\u201d), a biopharmaceutical company focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that Chief Executive Officer Howard J. Federoff, M.D., Ph.D., will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 \u2013 15, 2021. Dr. Federoff will deliver his corporate presentation on July 15 at 9:00am ET. To receive additional information, request an invitation or to schedule a one-on-one meeting, please email angie.goertz@issuerdirect.com. Investors can register here. About Brooklyn ImmunoTherapeutics Brooklyn is focused on exploring the role that cytokine-based &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-511741","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) &#8212; Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (\u201cBrooklyn\u201d or \u201cthe Company\u201d), a biopharmaceutical company focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that Chief Executive Officer Howard J. Federoff, M.D., Ph.D., will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 \u2013 15, 2021. Dr. Federoff will deliver his corporate presentation on July 15 at 9:00am ET. To receive additional information, request an invitation or to schedule a one-on-one meeting, please email angie.goertz@issuerdirect.com. Investors can register here. About Brooklyn ImmunoTherapeutics Brooklyn is focused on exploring the role that cytokine-based &hellip; Continue reading &quot;Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-12T12:18:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQ2NSM0MjkxNzYzIzIyMTAyODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021\",\"datePublished\":\"2021-07-12T12:18:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\\\/\"},\"wordCount\":262,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODQ2NSM0MjkxNzYzIzIyMTAyODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\\\/\",\"name\":\"Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODQ2NSM0MjkxNzYzIzIyMTAyODA=\",\"datePublished\":\"2021-07-12T12:18:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODQ2NSM0MjkxNzYzIzIyMTAyODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODQ2NSM0MjkxNzYzIzIyMTAyODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/","og_locale":"en_US","og_type":"article","og_title":"Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021 - Market Newsdesk","og_description":"NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) &#8212; Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (\u201cBrooklyn\u201d or \u201cthe Company\u201d), a biopharmaceutical company focused on exploring the role that cytokine and gene editing\/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that Chief Executive Officer Howard J. Federoff, M.D., Ph.D., will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 \u2013 15, 2021. Dr. Federoff will deliver his corporate presentation on July 15 at 9:00am ET. To receive additional information, request an invitation or to schedule a one-on-one meeting, please email angie.goertz@issuerdirect.com. Investors can register here. About Brooklyn ImmunoTherapeutics Brooklyn is focused on exploring the role that cytokine-based &hellip; Continue reading \"Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-12T12:18:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQ2NSM0MjkxNzYzIzIyMTAyODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021","datePublished":"2021-07-12T12:18:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/"},"wordCount":262,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQ2NSM0MjkxNzYzIzIyMTAyODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/","name":"Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQ2NSM0MjkxNzYzIzIyMTAyODA=","datePublished":"2021-07-12T12:18:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQ2NSM0MjkxNzYzIzIyMTAyODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQ2NSM0MjkxNzYzIzIyMTAyODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/brooklyn-immunotherapeutics-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-15-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=511741"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511741\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=511741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=511741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=511741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}